Presentations of the Second MELODI
MONDAY 18.10.10
Opening session
- Welcome Address by the Organizers
Jacques Repussard, IRSN/France, Gilles Bloch, CEA/France - Welcome Address by the MELODI Governing Board
Wolfgang Weiss, BfS/Germany - Welcome Address by the European Commission
Octavio Quintana Trias, EC; represented by André Jouve - Welcome Address by the WHO
Maria del Rozario Perez , WHO - Toxicology of the 21st century
Melvin E Andersen, the Hamner Institutes for Health sciences/USA - Genetic Approaches in Radiation-Induced Cancer
Marc Lathrop, CEA/France - Challenges of Low Dose Exposure in Medical Uses of Ionising Radiation
Klaus Rüdiger Trott, Andrea Ottolenghi, Vere Smyth, University Degli Studi, Pavia/Italy
Open Plenary Session 1: Non Cancer Effects - Lens Opacities
Jochen Graw, Helmholtz Center Munich/Germany - The Epidemiology and Radiobiology of Cardiovascular Diseases
Marc Little, National Cancer Institute (NCI)/USA
Low Dose Effects of Toxic Metal Compounds
Andrea Hartwig, Karlsruhe Institute of Technology/Germany
Effects of Low Dose in Immune System
Benoît Favier, CEA/France
Open Plenary Session 2: Individual Radiation Sensitivity for Cancer
The Impact of DNA Damage on Human Health
Jan H.J. Hoeijmakers, Erasmus Medical Center, Rotterdam/the Netherlands
Individual Sensitivity for Radiation-Induced Cancer
Janet Hall, Institut Curie, Inserm/France
Genetic Susceptibility of Radiation-Related Thyroid Cancer
Fumihiko Matsuda, Kyoto University/Japan
Individual Susceptibility and Clinical Reality
Jacques Balosso, CHU Grenoble/France
Open Plenary Session 3: Effects of Radiation Quality
Innovative Ultrafast Radiation Sources: Towards the Real-Time Nanodosimetry
Yann Gauduel, ENS/Inserm, France
Non-Targeted Dose Response Models and Space Travel
Francis A. Cucinotta, NASA/USA
Risk Associated to Uranium Exposure
Irina Canu, IRSN/France - Radiation Qualities in Carbon-Ion Radiotherapy at NIRS/HIMAC
Shunsuke Yonai, NIRS/Japan
TUESDAY 19.10.10
Open Working Group Sessions (OWGS)
- OWGS 1 Risks Associated to Uses of Ionizing Radiation for Medical Applications, Including Diagnosis and Therapy Procedures
Chair: François Paris, Inserm/France - OWGS 2 Biomarkers of Radiosensitivity
Chair: Penny Jeggo, University of Sussex/UK - OWGS 3 Biological Effects Resulting from an Internal Contamination with Low Dose of Radionuclides (Cancer and Non-Cancer Effects)
Chair: Isabelle Dublineau, IRSN/France - OWGS 4 Cell-Interactions Mediating Radiation Responses and Carcinogenesis
Chair: Mary Helen Barcellos-Hoff, New York Langone Medical Center/USA - OWGS 5 Stem Cells, Tissue Turnover and Low Doses
Franz Oesch, Mainz University/Germany; Chair: Ohtsura Niwa, BioMedics Japan Inc./Japan
OWGS 6 Brain/Neuronal Cell – Radiation Effects
Chair: Per Eriksson, Uppsala University/Sweden
WEDNESDAY 20.10.10
Reporting and Plenary Discussion Session
- Risks Associated to Uses of Ionizing Radiation for Medical Applications, Including Diagnosis and Therapy Procedures
François Paris, Inserm/France - Biomarkers or Radiosensitivity
Penny Jeggo, University of Sussex/UK - Biological Effects Resulting from an Internal Contamination with Low Dose of Radionuclides (Cancer and Non-Cancer Effects)
Isabelle Dublineau, IRSN/France - Cell-Interactions Mediating Radiation Responses and Carcinogenesis
Mary Helen Barcellos-Hoff, New York Langone Medical Center/USA - Stem Cells, Tissue Turnover and Low Doses
Ohtsura Niwa, BioMedics Japan Inc./Japan
Brain/Neuronal Cell – Radiation Effects
Per Eriksson, Uppsala University/Sweden
Strategic Research Agenda – Plenary Session - Report from the MELODI SRA Expert Group
Dietrich Averbeck, David Lloyd, Peter O’Neill - Conclusion
Wolfgang Weiss, BfS/Germany
Final Announcement & Programme
View document HERE.
First Announcement
Second International MELODI Workshop October 18-20, 2010
Paris, France First Announcement
This workshop will be the next major opportunity to:
- participate in the MELODI Low Dose Research Platform,
- contribute to the development of its Strategic Research Agenda (SRA),
- discuss new multidisciplinary research projects aiming to implement the SRA
Since the first MELODI workshop organised in Stuttgart in 2009 and sponsored by BfS, the European Low Dose Risk research strategy has made significant progress:
A new Network of Excellence, called DoReMi, has been set up between 12 partners for a duration of six years. Its launch meeting took place in Barcelona in January 2010. With a total budget of over 13 M€ (EC contribution), it is responsible for paving the way to European integration of R&T programmes in the field of low dose risks, for the development of the first steps of a Strategic Research Agenda (Called Transition Research Agenda) aimed at developing multidisciplinarity between radiobiology, dosimetry and epidemiology. Information will soon be available on www.doremi-noe.net.
The MELODI platform is currently being constituted in a fully open associative entity, open to all funding bodies and research organisations able and interested to contribute to the achievement of its goals. Applications to formal membership will be possible as soon as the statutes of the association are approved, in principle before summer 2010. The main goal of MELODI will be to develop and maintain a Strategic Research Agenda in the field of low dose radiation research and to actively promote and foster its implementation. This will be achieved by the MELODI membership and through cooperation with EU and Member States institutions, with WHO and IAEA at the international level and with interested R&T organisations in other regions of the world. Among the next steps is the constitution of a wide ranging Scientific Committee which will guide the development of the SRA and contribute to the independant scientific evaluation of research projects for the benefits of the MELODI platform member organisations.
The Paris MELODI Workshop will take place in the premises of Paris University, Boulevard Jourdan, from October 18 to 20. The agenda will comprise different types of sessions:
An opening session will inform the participants about the recent developments of the MELODI platform. The first General Assembly of the MELODI association will also take place, with the election of the Board and a presentation of the progress made in the development of the association and the achievement of its goals (governing rules, scientific advisory committee, first steps of operational integration of existing national programmes, MELODI website, …).
Plenary sessions will provide the attendants with keynote lectures by senior world level scientists addressing key questions, such as the system biology approaches, the toxicology of the 21st century or the challenges posed by the use of ionizing radiation for medical applications;
Parallel plenary sessions will invite the participants to discuss about recent developments of researches in topics such as non-cancer effects, individual radiation sensitivity as well as radiation quality;
Parallel working group sessions will offer the opportunity for scientists to work on more specific issues such as stem cells, biomarkers of sensitivity to cancer, bystander effects, cognitive effects, medical uses of ionizing radiation in conventional and interventional radiology and toxicological effects resulting from an internal exposure;
In a plenary reporting session the main outcomes of the working group sessions will be presented and discussed;
A second plenary session will give the chance for encouraging exchanges among scientists and their potential partners (industry, end-users, funding organisations), for informal discussions between participants aimed at visions for future research ventures needed to progress down the path of the Strategic Research Agenda.
Please save these important dates.
A full Workshop programme will be posted as soon as finalized, together with the practical arrangements for registration and participation. No fees will be charged for participation in the workshop, which is jointly organized and sponsored by IRSN and CEA on behalf of MELODI.
In the case of questions, please contact the following email address: